What Is a Pap Smear — and Why Do They Do It?
George Papanicolaou — a Greek-American physician — introduced the cervical smear in the 1940s after years of studying exfoliated cells. Before widespread pap screening, cervical cancer was one of the leading causes of cancer death in American women. Between 1975 and 2020, cervical cancer mortality in the US dropped by more than 50%. That decline is real. The pap smear is one of the more effective cancer screening tools ever developed — and that fact matters when evaluating everything else on this page.
What the test actually does: a provider uses an instrument to collect cells from the cervix — specifically from the transformation zone, the junction between two different cell types where most cervical cancers originate. Those cells are examined under a microscope for abnormal changes. In modern practice, the sample is also tested for HPV — human papillomavirus — because persistent high-risk HPV infection is the primary driver of the cell changes that, over years to decades, can develop into cervical cancer.
The purpose of the test is surveillance — catching changes early, before they become cancer. That is a legitimate and well-evidenced goal. The informed consent problem is not with the goal. It is with what women are not told about the tools used, the chemicals applied, the cascade that follows a positive result, and the vaccine pushed as prevention — before any of it happens.
You can't consent to what you've never been told.
HPV: What the Test Measures and What It Does Not Tell You
HPV — human papillomavirus — is sexually transmitted, extremely common, and in most cases self-limiting. Estimates are that 80% of sexually active adults will test positive for HPV at some point in their lives. In the overwhelming majority of cases, the immune system clears the infection within two years without any intervention and without the person ever knowing they carried it.
The link between persistent high-risk HPV (particularly HPV 16 and 18) and cervical cancer is real and established. Persistent infection — not initial infection — is the relevant variable. A positive HPV test does not mean the virus is persisting. It means the virus is present at the moment of sampling.
The factors that convert a transient HPV infection into a persistent one — and ultimately into cervical dysplasia — include immune status, nutritional status, smoking, and notably: long-term oral contraceptive use. Studies have found that women who use oral contraceptives for five or more years have approximately 2–4x the risk of cervical cancer compared to non-users with the same HPV exposure. This is documented in the literature. It is not disclosed when OCs are prescribed, and it is almost never raised in the context of an abnormal pap result in a woman who has been on hormonal contraception.
Folate metabolism is also relevant. The MTHFR gene variant — present in a significant portion of the population — reduces the ability to convert dietary folate to its active form (5-methyltetrahydrofolate). Folate is involved in cervical cell DNA synthesis and repair. Women with MTHFR variants and low folate status show higher rates of HPV persistence and dysplasia. This is not the conversation that happens after an abnormal pap result.
The HPV Vaccine: What the Trials Did Not Show You
The HPV vaccine is presented as the solution to the HPV problem — and therefore, implicitly, the solution to the abnormal pap problem. Before accepting that framing, there are several things worth knowing that are not disclosed at the point of recommendation.
The Placebo Was Not a Placebo
In the pre-licensure clinical trials for Gardasil, the "placebo" group did not receive an inert saline injection. They received AAHS — amorphous aluminum hydroxyphosphate sulfate — the exact aluminum adjuvant contained in the vaccine itself.
This is documented in the FDA's own briefing documents for the pre-licensure review. A genuine placebo-controlled trial compares the intervention against something inert. Using the adjuvant as the control means that adverse events occurring in the "placebo" group — the aluminum-injected group — are absorbed into the background rate. The two groups appear to have similar adverse event profiles. The interpretation: the vaccine is as safe as placebo. The reality: neither group had a clean baseline. The aluminum was never isolated as a variable.
Source: FDA Vaccines and Related Biological Products Advisory Committee briefing document, June 2006 (VRBPAC). Available on fda.gov.
Coverage: A Fraction of Known Strains
There are more than 200 known strains of HPV. Approximately 40 infect the genital tract. Of those, roughly 14 are classified as high-risk oncogenic strains capable of contributing to cervical cancer. The original Gardasil (2006) covered 4 strains: HPV 6, 11, 16, and 18. Gardasil 9 (2014) expanded to 9 strains: 6, 11, 16, 18, 31, 33, 45, 52, and 58.
HPV 16 and 18 together account for approximately 70% of cervical cancers. The remaining 30% are caused by strains not covered by the vaccine. A vaccinated woman who understands this will continue regular screening. A woman who has been told "you're protected against cervical cancer" — as the marketing implies — may not. The CDC has acknowledged that vaccinated women still require pap smears. This is not consistently communicated.
Vaccinating against dominant strains raises an additional concern: ecological niche replacement. When the most prevalent high-risk strains are suppressed by widespread vaccination, other oncogenic strains may fill the vacant niche in the HPV population. Post-vaccination surveillance studies are monitoring for this. It has not been dismissed. It has not been resolved.
The Pre-Existing Infection Problem
The FDA's own pre-licensure data showed that in women who were already HPV-16 or HPV-18 positive at the time of vaccination, vaccinated women had higher rates of CIN2+ (high-grade precancerous lesions) than unvaccinated women in the same subgroup.
This is not a fringe finding. It is in the FDA briefing documents. The agency noted it. The explanation offered was that vaccination in women with active infection does not provide benefit — and the data suggested it may cause harm in that subgroup. The current guidance is that the vaccine is most effective before sexual debut. What this means in practice: a significant proportion of the women receiving the vaccine — including adult women, for whom the approved age was extended to 45 in 2018 — may already carry one or more of the covered strains and are receiving no benefit, and potentially accelerated progression in affected tissue.
Pre-vaccination HPV testing is not standard practice before administering the series.
Deaths and Serious Adverse Events: Trial Data and Post-Licensure Reporting
Deaths During the Pre-Licensure Trials — Vaccine Group vs. "Placebo" Group
| Group | Deaths Reported | What They Received |
|---|---|---|
| Vaccine group | 15 | Gardasil (HPV antigens + AAHS aluminum adjuvant) |
| "Placebo" group | 15 | AAHS aluminum adjuvant alone — not saline, not inert |
Source: FDA VRBPAC briefing document, June 2006. The equal death count between groups was used as evidence the vaccine was safe. The problem: both groups received aluminum. Neither group had a clean baseline. The aluminum was never isolated as a variable. Fifteen deaths in each arm of a trial for a vaccine targeting a virus that rarely causes cancer in screened populations — and this was presented as a safety signal clearance.
All 30 deaths — across both groups — were classified by Merck as unrelated to the vaccine. That determination was made by the manufacturer, not by independent investigators. The FDA accepted the framing because the two groups looked comparable. They looked comparable because both were receiving aluminum.
Post-licensure, the FDA and CDC jointly operate VAERS — the Vaccine Adverse Event Reporting System. Reporting is voluntary and passive. A Harvard Pilgrim Health Care study (Lazarus R et al., 2011, commissioned by the Department of Health and Human Services) concluded that fewer than 1% of vaccine adverse events are ever reported to VAERS. VAERS data cannot establish causation — a report means the event occurred after vaccination, not that the vaccine caused it. What it can do is identify safety signals for further investigation.
VAERS Data for Gardasil HPV Vaccine — Through 2023
Source: VAERS Wonder (CDC/FDA joint database, wonder.cdc.gov — publicly searchable). Applying Harvard Pilgrim <1% reporting rate estimate. VAERS reports correlation only — not confirmed causation.
| Adverse Event Category | VAERS Reported | Estimated Actual (÷ 1%) |
|---|---|---|
| Deaths | ~310 | ~31,000 |
| Life-threatening events | ~830 | ~83,000 |
| Permanent disability | ~1,700 | ~170,000 |
| Hospitalizations | ~3,200 | ~320,000 |
| Emergency room visits | ~16,600 | ~1,660,000 |
| Total reports (all severity) | ~66,000 | ~6,600,000 |
The Comparison the Benefit Side Requires
Source: CDC, American Cancer Society. US data. Cervical cancer deaths include all HPV strains — vaccine covers approximately 70% (HPV 16 and 18).
In the United States, where regular pap screening exists, Dr. Diane Harper — one of the principal researchers who developed Gardasil — has stated that the mortality benefit of adding the HPV vaccine on top of existing screening programs is negligible. Cervical cancer deaths in the US are predominantly in women who have never been screened or have not been screened recently. The vaccine does not replace that gap. The pap smear, for all its problems documented on this page, remains the intervention with the most direct evidence for cervical cancer mortality reduction in screened populations.
The risk conditions documented in VAERS for Gardasil include: autoimmune disorders, premature ovarian insufficiency, postural orthostatic tachycardia syndrome (POTS), complex regional pain syndrome (CRPS), Guillain-Barré syndrome, seizure disorders, and death. These are not confirmed causal relationships. They are reported temporal associations. At 1% reporting, the question of whether a meaningful signal is present in this data has not been adequately investigated.
The question no one asks at the appointment: If HPV is cleared spontaneously in the vast majority of cases, and the vaccine covers a fraction of oncogenic strains, and the trials used the adjuvant as the placebo, and women who already carry the covered strains may show accelerated lesion progression — what specifically is the risk-benefit calculation for this individual, at this age, with this exposure history? That conversation has never happened at scale. The recommendation is universal.
The Brush Has Changed — And Not in Your Favor
The original pap smear used a wooden Ayre spatula — a flat, slightly curved wooden stick — swept across the cervix, with a separate cotton-tipped swab inserted into the endocervical canal. Cells were smeared directly onto a glass slide and read under a microscope. It was a relatively low-trauma procedure. The old wooden spatula and cotton swab are now largely gone.
They have been replaced by:
The Cervex-Brush / Broom-Type Brush
A plastic brush with a central stem and radiating bristles. It is rotated five full turns against the transformation zone — the squamocolumnar junction where columnar and squamous cells meet, and where dysplastic changes originate. The brush is then either smeared onto a slide or swirled into a liquid vial (ThinPrep / liquid-based cytology). The transformation zone is not an inert surface. It is active, permeable tissue with direct access to the cervical stroma and lymphatic drainage.
The Cytobrush (Endocervical Brush)
A thinner brush inserted directly into the endocervical canal — the opening of the uterus — and rotated to collect cells from the canal lining. This accesses tissue that was not reached by the original cotton swab. The endocervical canal is narrow, sensitive tissue. Insertion causes cramping that is often significant and not well-disclosed in advance. Bleeding from this sampling is common and expected — which is a way of saying the tool is causing tissue disruption by design.
Liquid-based cytology (LBC) — sold as ThinPrep or SurePath — was marketed as more accurate and more sensitive than the old slide smear. What is less discussed: "more sensitive" also means more false positives — more women flagged for follow-up procedures for changes that would have resolved spontaneously.
ThinPrep / LBC vs. Conventional Pap — The Sensitivity-Specificity Tradeoff
Sources: Arbyn M et al., Eur J Cancer 2008; Nanda K et al., Ann Intern Med 2000 (meta-analysis); Ronco G et al., Lancet Oncol 2010 (NTCC trial). "False positive rate" refers to ASCUS/LSIL results that do not progress to CIN2+ on follow-up.
| Conventional Pap (Ayre spatula) | LBC / ThinPrep | |
|---|---|---|
| Sensitivity for CIN2+ | ~53–65% | ~61–73% |
| Specificity (true negatives) | ~97% | ~95–96% |
| ASCUS detection rate | ~3–4% | ~5–7% |
| ASCUS cases that progress to CIN2+ | ~10–15% (both methods) | |
| ASCUS cases that regress spontaneously | ~60–70% within 2 years (both methods) | |
| Women sent to colposcopy who have no CIN2+ | lower (higher specificity) | higher — the key tradeoff |
The specificity drop of 1–2% sounds small. Applied to the 50+ million pap smears performed annually in the US, it translates to hundreds of thousands of additional ASCUS/LSIL results per year — each one initiating the cascade of repeat paps, colposcopy, acetic acid burns, punch biopsies, and Monsel's solution application — for changes the body would have resolved on its own.
Ethylene Oxide: What the Brush Is Sterilized With
Ethylene oxide is classified by the IARC as a Group 1 carcinogen — a known human carcinogen.
The same classification as asbestos, benzene, and tobacco smoke. Ethylene oxide (EtO) is the dominant sterilization method for medical devices that cannot withstand heat or steam — including plastic pap smear brushes, IUD inserters, biopsy instruments, and catheter kits. It is colorless, odorless at low concentrations, and penetrates packaging thoroughly — which is precisely why it works as a sterilant.
The FDA allows residual EtO levels on medical devices after sterilization — levels that are considered acceptable for devices touching intact skin or general tissue. The cervix is not intact skin. It is highly permeable mucosal tissue with direct access to the uterine cavity. The transformation zone — which the pap brush specifically targets — is among the most biologically active tissue in the female reproductive tract.
There is no requirement that this be disclosed. Your provider does not tell you before inserting a brush against your cervix that the brush was manufactured using a process that leaves traces of a Group 1 carcinogen on its surface. The FDA says the residual levels are within acceptable limits. But acceptable limits are calculated for average exposures — not for direct application to cervical mucosa in a woman receiving annual screenings for decades.
The Sterigenics scandal — in which ethylene oxide emissions from medical device sterilization plants were linked to elevated cancer rates in surrounding communities in Georgia, Illinois, and other states — brought EtO into public awareness briefly between 2018 and 2022. The mechanism that made those communities sick is the same mechanism that is present on the surface of instruments placed inside women's bodies. The question is one of dose and proximity, not of mechanism.
Other sterilization methods exist — gamma irradiation, electron beam, vaporized hydrogen peroxide, dry heat. They are used less often for plastic devices because EtO is cheaper and more penetrating. The tradeoff is not one you were asked to consent to.
The Cascade That Follows a Positive Result
Most women who get an abnormal pap result experience a level of fear disproportionate to the actual finding — because the language used ("abnormal cells," "cervical dysplasia," "precancerous") does not convey probability. The vast majority of cervical cell changes, including low-grade squamous intraepithelial lesions (LSIL) and even some high-grade lesions (HSIL), resolve spontaneously without intervention when the immune system is functioning.
The procedures that follow an abnormal result include, in escalating order:
Repeat Pap / HPV Co-Testing
Additional sampling at 3–6 month intervals. Each instance repeats the brush exposure — the EtO residue, the mechanical trauma to the transformation zone, the endocervical canal insertion.
Colposcopy
A lighted magnifying scope is placed at the vaginal opening while the provider examines the cervix. This alone is relatively low-trauma — but colposcopy is almost always accompanied by:
- Acetic acid (white vinegar) application — swabbed directly onto the cervix to cause abnormal cells to whiten (acetowhitening). This is an acidic burn. It causes a chemical reaction in the tissue. Women report significant burning during this step. It is presented as routine.
- Lugol's iodine application — a second chemical agent painted onto the cervix; normal cells stain brown, abnormal cells appear yellow. Another direct chemical application to the most sensitive mucosal tissue in the reproductive tract.
- Punch biopsy — a forceps-style instrument removes small pieces of cervical tissue. Typically done without local anesthesia. The standard language given to patients is "you'll feel a pinch or cramp." The reality for many women is acute pain, significant cramping, and bleeding lasting days.
LEEP — Loop Electrosurgical Excision Procedure
A thin wire loop carrying electrical current is used to cut away and cauterize a cone of cervical tissue containing the transformation zone. It is performed for HSIL (high-grade dysplasia) or persistent abnormal findings. The electrical current causes thermal necrosis at the margins — tissue is burned away. A strong-smelling smoke evacuator is used during the procedure to remove the plume of burning tissue.
What is almost never disclosed before LEEP: the procedure has documented reproductive consequences. Multiple studies — including a 2008 British Journal of Obstetrics and Gynaecology meta-analysis (Kyrgiou et al.) — found that LEEP increases the risk of preterm birth in subsequent pregnancies by approximately 2–3 times. The cervix plays a structural and immunological role in pregnancy. Removing tissue changes the mechanics of cervical competence and the microbial environment of the cervical canal.
This information is material to a woman who plans to have children. It is routinely omitted from pre-procedure conversations. The consent form, if one exists, uses language — "may affect future pregnancy outcomes" — that does not communicate what "2–3x increased preterm birth risk" actually means for a specific woman making a specific decision.
Cold Knife Conization (CKC)
A surgical cone biopsy performed in an operating room under general or regional anesthesia. A scalpel removes a cone-shaped section of the cervix. More tissue is removed than in LEEP. Reproductive consequences — cervical incompetence, preterm labor, pregnancy loss — are even more pronounced than with LEEP. This is typically reserved for the most severe dysplasia or for adenocarcinoma in situ.
The key question that is almost never asked: what was the natural history of this lesion without intervention? For LSIL, regression rates without treatment are documented at 60–70% within two years. For HSIL, regression is less common — but the decision about whether to intervene, and when, involves a probability calculation that women are rarely given the numbers to make for themselves.
Punching a Bruise and Calling It Treatment
Here is the logical problem no one names out loud.
The transformation zone — the tissue the pap brush specifically targets — is one of the most biologically reactive tissues in the female body. It is the junction between two cell types, actively permeable, immunologically sensitive, and designed to respond to insult. When you apply a Group 1 carcinogen-residue instrument to that tissue and rotate it five times, the tissue responds. When you follow that with an acetic acid burn, the tissue responds. When you return six months later and do it again, the tissue responds again. Each response involves cellular changes — altered mitosis, inflammatory infiltrate, microabrasion repair, epithelial remodeling.
The central paradox: the procedures used to detect and treat cervical dysplasia are themselves capable of producing the tissue changes being screened for.
Acetic acid application causes localized chemical burn to cervical epithelium. Punch biopsy removes tissue without anesthesia and leaves a wound that must heal. LEEP uses electrical current to burn away the transformation zone entirely. Each of these events triggers exactly the kind of inflammatory, proliferative cellular response that, when sampled and read on a slide, is classified as dysplasia or precancerous change. The question that is almost never asked is: how much of the "abnormal" finding at the follow-up visit is a response to the previous procedure?
This is not a fringe concern. It is basic tissue physiology. A tissue that has been repeatedly traumatized — mechanically abraded, chemically burned, biopsied, and cauterized — will exhibit cellular atypia during the healing process. That atypia will be sampled at the next screening. That sampling will use the same carcinogen-sterilized instrument against the same already-compromised tissue. The finding of "persistent dysplasia" initiates a more aggressive intervention. The cycle deepens.
The immune system's job is to respond to threat. Exposing mucosal tissue to a known carcinogen and then interpreting the immune response as the disease — rather than as evidence that the tissue is doing exactly what tissue does — is not screening. It is provocation followed by punishment for reacting.
A woman whose "abnormal cells" resolved spontaneously — which, for low-grade changes, happens in 60–70% of cases within two years — will never know whether they resolved because of the screening or in spite of it. The one who proceeds through the cascade will have a medical record that shows progressive intervention. Neither will be told that watchful waiting was an option, that immune support and folate status were relevant variables, or that the procedure itself may have been part of what her cervix was responding to.
What Gets Applied After the Biopsy: Monsel's Solution
After a punch biopsy of the cervix, the provider needs to stop the bleeding. The standard agent used is Monsel's solution — ferric subsulfate (Fe₄(OH)₂(SO₄)₅) at 20% concentration, pH approaching 1. It is swabbed directly onto the open biopsy site. It works quickly, it is cheap, and it has been in use for decades. Those are essentially the full reasons for its use.
Ferric subsulfate is an iron compound applied at near-zero pH directly to open cervical tissue. Iron is one of the most well-documented oxidative carcinogens in human biochemistry. The downstream mechanism — the Fenton reaction — is the same pathway implicated in hemochromatosis-linked liver cancer, asbestos-fiber-linked mesothelioma, and endometriosis-linked ovarian cancer.
What It Does to the Tissue
The extremely low pH causes coagulation necrosis in cervical stroma to a depth of 0.6 mm — meaning the iron penetrates below the surface into the underlying connective tissue, not just the wound surface. Ferric ions are deposited within fibrin networks and collagen fibers — a process called ferrugination — and are engulfed by macrophages (siderophages) that accumulate at the site. These iron-laden macrophages persist in the cervical stroma for up to three months. The iron deposits are so persistent and so visually dramatic that pathologists have a specific term for them: Monsel's tattoo.
The iron doesn't just sit there passively. Davis JR et al. (American Journal of Clinical Pathology, 1984) documented that Monsel's application impedes re-epithelialization for up to two weeks and can provoke a foreign body giant cell reaction. Spitzer and Chernys (American Journal of Obstetrics and Gynecology, 1996) found that artifacts from Monsel's in subsequent cervical biopsies taken within 18 days were definitive and diagnostically confusing. Two published case reports document reactions so severe the Prussian-blue-positive iron deposits mimicked frank cervical malignancy on cytology, triggering further investigation and near-misdiagnosis of cancer that wasn't there.
The Iron Problem: Fenton Chemistry in Cervical Stroma
Ferric iron (Fe³⁺) — the form in Monsel's solution — is reduced to ferrous iron (Fe²⁺) by cellular reducing agents: ascorbate, superoxide, and normal tissue metabolism. Fe²⁺ then drives the Fenton reaction:
The hydroxyl radical (OH•) produced by this reaction is the most reactive oxygen species in biology. Unlike superoxide or hydrogen peroxide — which are relatively selective — the hydroxyl radical reacts with essentially any organic molecule at near-diffusion-limited rates. It attacks DNA at all four nucleobases simultaneously, producing a DNA lesion called 8-oxo-2'-deoxyguanosine (8-oxodG), which causes the specific point mutation pattern (G:C → T:A transversions) seen in many carcinomas. It also attacks lipid membranes and protein structures.
The reaction is self-perpetuating: Fe³⁺ produced in the Fenton reaction is recycled back to Fe²⁺ by superoxide (the Haber-Weiss cycle), meaning a small amount of iron can generate hydroxyl radicals continuously as long as H₂O₂ and superoxide are available — which they are in every metabolically active cell. H₂O₂ is a normal byproduct of mitochondrial respiration in every cell of the cervical transformation zone.
What the Iron Carcinogenesis Literature Shows
This is not a theoretical concern. The research base is substantial:
Hemochromatosis → hepatocellular carcinoma at 219–240× the rate of controls
Occurring even in noncirrhotic patients — meaning iron-mediated oxidative DNA damage, not cirrhosis-related architectural damage, is the primary driver. (Toyokuni S, Cancer Science, 2009)
Iron-containing asbestos fibers are more carcinogenic than iron-free asbestos fibers
Local iron overload at the fiber surface drives mesothelioma — the same Fenton mechanism. (Toyokuni S, Cancer Science, 2009)
Endometriotic cysts → elevated ovarian cancer risk via catalytic iron
Endometriotic cysts accumulate free catalytic iron from repeated hemorrhage. Adjacent epithelium shows elevated 8-oxodG (oxidative DNA damage marker). Women with endometriosis have elevated risk of clear cell and endometrioid ovarian adenocarcinoma. The pathway: iron → Fenton → 8-oxodG → mutation → cancer. This is the closest published analog to what occurs at a Monsel's-treated cervical biopsy site. (Toyokuni S, Cancer Science, 2009; Yamaguchi K et al., PNAS, 2008)
Iron-mediated damage specifically targets p16/INK4A — a key tumor suppressor in cervical cancer
In a rat model of iron-mediated carcinogenesis, the p16 locus showed allelic loss in 37.2% of cells after one week of iron exposure vs. 22.5% in controls (p < 0.001). p16/INK4A loss removes the G1/S checkpoint — cells with damaged DNA replicate instead of undergoing apoptosis. p16 silencing is one of the earliest and most common events in cervical cancer progression. (Hiroyasu M et al., American Journal of Pathology, 2002)
Elevated iron stores reduce HPV clearance by 27–66%
In a cohort of 327 women with 494 incident HPV infections, elevated ferritin reduced the probability of clearing oncogenic HPV by 27% overall, and reduced HPV-16 clearance dramatically (adjusted hazard ratio 0.34 for the highest iron group). The proposed mechanisms: iron-generated ROS directly alter HPV transcriptional activity; ROS impair immune surveillance in local tissue. (Siegel EM et al., Cancer Epidemiology Biomarkers & Prevention, 2012. PMC3709556)
To be precise: no published study has directly measured Fenton reaction products in cervical tissue adjacent to Monsel's-induced iron deposits, or measured whether Monsel's application increases cervical cancer risk in a prospective cohort. That study has not been done. What exists is extensive mechanistic literature establishing that iron in tissue generates hydroxyl radicals via Fenton chemistry, that this mechanism causes cancer in multiple tissue types by the same pathway, that the specific tumor suppressors silenced are the same ones lost in cervical cancer progression, and that elevated iron specifically impairs clearance of the virus causally linked to cervical cancer.
The alternative exists and has been documented.
Aluminum chloride achieves equivalent hemostasis at colposcopy biopsy sites, causes significantly less tissue pigmentation, does not deposit redox-active iron, and does not drive Fenton chemistry. Pressure alone is adequate for most punch biopsies. Electrocautery achieves hemostasis thermally — no foreign material is deposited and no ferrugination occurs. Monsel's is used because it is cheap, fast, and familiar. Not because it is the safest option for a tissue that is already HPV-exposed, already at risk, and about to be re-biopsied.
The Speculum, the Lubricant, and the Plastic
Metal speculums are still used in many practices; plastic disposable speculums have become common in others. Disposable plastic speculums are typically made from polypropylene or polystyrene — neither of which is inert in the context of warm, moist mucosal tissue under mechanical pressure.
Lubricants used to ease speculum insertion have historically been a concern: standard medical lubricants (KY Jelly, Surgilube) contain parabens, propylene glycol, and chlorhexidine in some formulations — antiseptics and preservatives applied to vaginal tissue. Many practices now use water alone or have moved to paraben-free formulations, but practice varies widely and patients are rarely informed of what is being applied.
The speculum compresses and stretches the vaginal walls under tension for the duration of the exam. In post-menopausal women with atrophied tissue, this can cause microabrasions and pain that is reported as "expected" rather than as tissue injury worth preventing or acknowledging.
Supporting Cervical Health Without the Panic
None of this is a reason to refuse all gynecological screening. It is a reason to enter every procedure with full information, to ask specific questions, and to understand that an abnormal result initiates a conversation — not an automatic treatment plan.
Questions worth asking before agreeing to a procedure:
- ●What is the likelihood that this finding resolves on its own within 12 months without intervention?
- ●If I wait and repeat the pap in 6 months, what is the risk that waiting causes harm vs. the risk the procedure itself causes harm?
- ●What are the reproductive consequences of LEEP if I plan to have children?
- ●What sterilization method was used on these instruments?
- ●What is in the lubricant being used?
- ●Can I be given local anesthesia before a punch biopsy?
Cervical health is supported by the same inputs that support every other tissue in the body: immune function, whole-food nutrient status, hormonal balance, and elimination of known cofactors. Folate from real food (dark leafy greens, liver, legumes) rather than folic acid fortification supports the DNA repair processes relevant to dysplasia. Removing oral contraceptives as a cofactor — or at minimum knowing they are one — is material information.
The body's immune system has cleared HPV millions of times without a single LEEP procedure. The question is always: what is compromising that immune response? Answer that question, and the pap smear becomes one data point in a much larger picture — rather than the opening move in a surgical cascade.
Gynecological Instruments: What They Are and What They Do
A reference guide to the tools used in routine gynecological procedures — what each one is, what it does to the tissue, and what is not typically disclosed before use.
Vaginal Speculum
Duck-bill retractor · Metal or plastic
What it is: A hinged instrument inserted into the vaginal canal and cranked open to hold the vaginal walls apart and expose the cervix. Available in multiple sizes. Metal versions are autoclave-sterilized; plastic versions are single-use and manufactured from polypropylene.
What it does to tissue: Compresses and stretches vaginal epithelium under mechanical tension. In women with atrophy (post-menopause, post-partum, low estrogen), the tissue is less elastic and microabrasions are common. The insertion itself requires lubrication against mucosal tissue.
Not typically disclosed: Plastic speculums are manufactured from petroleum-derived polymers and are sterilized (or not — many arrive pre-packaged but not sterile) using processes that may leave chemical residues. The lubricant applied may contain parabens, propylene glycol, or chlorhexidine depending on brand and practice.
Cervical Brush (Cervex-Brush / Rovers Cervex-Brush)
ThinPrep / Liquid-Based Cytology · Plastic bristle brush
What it is: A broom-shaped plastic brush with fine nylon bristles, rotated five clockwise turns against the transformation zone of the cervix to collect squamous and glandular cells. The brush is then inserted into a vial of liquid preservative (ThinPrep or SurePath solution) or smeared on a slide.
What it does to tissue: Physical abrasion of the transformation zone — the biologically active junction between the outer cervical lining (squamous) and the canal lining (columnar). Rotation collects cells by disruption. Minor bleeding is common and expected.
Sterilization: Plastic devices that cannot be autoclaved are routinely sterilized using ethylene oxide (EtO) gas — IARC Group 1 carcinogen. Residual EtO levels on medical devices are regulated, but limits are calculated for devices in contact with intact skin, not for devices in direct contact with permeable cervical mucosa during reproductive-age annual screenings over decades.
Not typically disclosed: The EtO sterilization process. The permeable nature of the tissue being contacted. The fact that "a little spotting is normal" means the instrument caused bleeding by design.
Cytobrush (Endocervical Brush)
Endocervical sampling · Small bristle brush
What it is: A smaller, thinner brush inserted directly into the cervical os (the opening of the uterus) and rotated to sample endocervical canal cells. Used in conjunction with the cervical brush or as a standalone endocervical collection device.
What it does to tissue: Accesses the endocervical canal — narrow tissue with direct continuity with the uterine cavity. Rotation causes mechanical disruption and cramping that is frequently described as sharp, intense, or significantly painful. Not limited to "a pinch."
Not typically disclosed: That this brush goes inside the cervical canal, not just against the outer cervix. That the cramping is from endocervical tissue disruption. That EtO sterilization applies here as well.
Colposcopy + Acetic Acid + Lugol's Iodine
Follow-up to abnormal pap · Chemical + optical assessment
What it is: A lighted magnifying scope positioned at the vaginal opening. Combined with two chemical applications to the cervix: 3–5% acetic acid (white vinegar solution) and Lugol's iodine (potassium iodide solution). Both are used to differentiate normal from potentially abnormal tissue visually.
What it does to tissue: Acetic acid causes acetowhitening — a reversible change in cell appearance due to protein coagulation caused by the acid. It also causes a burning sensation reported by a significant proportion of women. Lugol's iodine is an irritant to mucous membranes. Both are applied with cotton-tipped applicators or forceps — direct chemical exposure to the cervix.
Not typically disclosed: That "acetowhitening" is a chemical burn mechanism. That the burning sensation is from acid on mucosal tissue. That these chemicals are being applied to the same transformation zone involved in cervical cancer risk — and that the long-term effect of repeated acid applications to that tissue is not formally studied.
Cervical Punch Biopsy (Tischler Forceps / Eppendorfer Forceps)
Colposcopy-directed biopsy · Forceps instrument
What it is: A small biting forceps that removes 2–4mm tissue cores from the cervix at areas identified during colposcopy. Multiple samples are typically taken in a single session. The tissue is sent for histopathological analysis (the "biopsy" that follows the pap and colposcopy).
What it does to tissue: Mechanical removal of cervical tissue without anesthesia in most outpatient settings. Women are told to expect "a pinch." The actual experience ranges from mild cramping to acute sharp pain and significant cramping, followed by bleeding for 1–5 days. Cervical tissue has pain-sensing nerves; this is not painless tissue removal.
Not typically disclosed: That local anesthesia is available and can be requested. That multiple cores may be removed. That the post-procedure discharge may be dark (from the Monsel's solution — ferric subsulfate — applied to stop bleeding, which is itself a heavy-metal compound applied to open tissue).
LEEP Wire — Loop Electrosurgical Excision Procedure
Excisional treatment · Electrical current · Tissue removal
What it is: A thin wire loop attached to an electrosurgical generator. The loop is heated by high-frequency electrical current and used to excise the transformation zone — cutting through cervical tissue while simultaneously cauterizing the edges. A separate "ball" electrode is used to cauterize remaining bleeding points. The procedure takes approximately 15–20 minutes and is typically performed under local anesthesia injected into the cervix.
What it does to tissue: Removes a cone of cervical tissue. The electrical current produces thermal necrosis at the cut margins. A surgical smoke plume is generated from burning tissue — evacuated via suction. The cervix heals over weeks, but the structural and immunological role of the removed tissue is permanently altered.
Reproductive consequences: A 2008 systematic review and meta-analysis (Kyrgiou et al., BJOG) of studies including over 27,000 women found that LEEP was associated with a significant increase in preterm birth (RR approximately 1.7), low birth weight, and premature rupture of membranes. Subsequent meta-analyses have confirmed these findings. The risk increases with larger excisions and repeat procedures. The cervical mucus plug — which the excised tissue helps form — is part of the uterine immune barrier during pregnancy.
Not typically disclosed: The specific preterm birth risk data. That this information is material for any woman who plans future pregnancies. That the consent form language ("may affect future pregnancies") does not quantify the risk in a meaningful way. That watchful waiting — repeat cytology at 6-month intervals — is a clinically supported alternative for many HSIL cases in women planning pregnancies.
IUD Inserter (Tenaculum + Sound + Introducer)
IUD placement · Multiple instruments · Uterine access
What it is: IUD insertion involves three to four instruments in sequence: a tenaculum (a clamp with teeth that grips the cervix), a uterine sound (a thin rod inserted to measure uterine depth), and the IUD introducer (the tube through which the IUD is pushed into the uterine cavity). Some providers also use a speculum dilator if the cervical os is narrow.
What it does to tissue: The tenaculum punctures the cervix with two prongs to stabilize it — this is where a significant portion of IUD insertion pain originates, though it is frequently described beforehand only as "some cramping." The uterine sound passes through the internal cervical os and into the uterine cavity. Vasovagal episodes (loss of consciousness from the pain and cervical stimulation) are well-documented and common enough to warrant monitoring after insertion — but are often presented as rare.
Not typically disclosed: That the tenaculum punctures (not just grips) the cervix. That misoprostol — a uterotonic drug — is sometimes given without informed consent to soften the cervix. That vasovagal syncope is common enough that lying down for 10–15 minutes post-insertion is standard practice, yet the reason why is rarely explained. That all instruments in this sequence are manufactured using processes that include EtO sterilization.
On Monsel's Solution (Ferric Subsulfate)
Applied after punch biopsies and LEEP to stop bleeding, Monsel's solution is a paste of ferric subsulfate — an iron-based compound. It causes a thick dark discharge for several days post-procedure ("looks like coffee grounds" is the standard description offered, when any description is offered at all). It is an astringent hemostatic agent applied to open cervical tissue. The iron-based composition and the dark discharge are almost never explained in advance — leaving many women frightened by what they were not told to expect.
Research & References
Studies Referenced
Kyrgiou M et al. — Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions
The Lancet, 2006 / BJOG 2008 meta-analysis · LEEP and preterm birth risk · n=27,000+ women
IARC Monographs Volume 60 — Ethylene Oxide
International Agency for Research on Cancer · Group 1 Classification (known human carcinogen)
Moreno V et al. — Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection
The Lancet, 2002 · Collaborative re-analysis: 10 case-control studies · 2–4× risk increase with 5+ year OC use
Butterworth CE et al. — Folate deficiency and cervical dysplasia
JAMA, 1992 · Folate, MTHFR status, and cervical epithelial changes
Tainio K et al. — Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance
BMJ, 2018 · CIN2 regression rates under observation · 50%+ regress within 2 years
EPA / Sterigenics — Ethylene Oxide Sterilization Facilities and Community Cancer Risk
U.S. EPA investigations 2018–2022 · Willowbrook IL, Covington GA · elevated cancer clusters near EtO facilities
Ferric Subsulfate (Monsel's Solution) & Iron Carcinogenesis
Davis JR et al. — Effects of Monsel's Solution in Uterine Cervix
American Journal of Clinical Pathology, 1984;82(3):332–335. PMID 6380272 · Ferrugination, coagulation necrosis, iron-laden siderophages persisting up to 3 months, impaired re-epithelialization, foreign body giant cell reactions
Spitzer M, Chernys AE — Monsel's Solution-Induced Artifact in the Uterine Cervix
American Journal of Obstetrics and Gynecology, 1996;175(5):1204–7. PMID 8942489 · Definitive biopsy artifacts up to 18 days post-application; clinical recommendation to wait 3+ weeks before re-biopsy
Toyokuni S — Role of Iron in Carcinogenesis: Cancer as a Ferrotoxic Disease
Cancer Science, 2009;100(1):9–16. PMID 19038044 · Hemochromatosis → HCC at 219–240× rate; asbestos iron model; endometriosis-ovarian cancer iron pathway; catalytic iron and p16-specific DNA damage
Hiroyasu M et al. — Specific Allelic Loss of p16 INK4A after Iron-Mediated Oxidative Damage
American Journal of Pathology, 2002;160(2):419–424. PMID 11839561 · p16 allelic loss in 37.2% of iron-exposed cells vs. 22.5% controls at 1 week; specific genomic vulnerability of tumor suppressor loci to Fenton chemistry
Siegel EM et al. — Iron Storage and Clearance of Incident HPV Infection
Cancer Epidemiology Biomarkers & Prevention, 2012;21(5):859–865. PMID 22426142 · Elevated ferritin reduced HPV clearance 27%; HPV-16 clearance AHR 0.34 in highest iron group; iron-ROS impairs local immune surveillance
HPV Vaccine — Primary Sources
FDA VRBPAC Briefing Document — Gardasil Pre-Licensure Review
Vaccines and Related Biological Products Advisory Committee, June 2006 · FDA.gov · Documents AAHS adjuvant use as control; includes pre-existing HPV infection subgroup data showing elevated CIN2+ in vaccinated women already positive at baseline
Gardasil 9 Package Insert (FDA-approved labeling)
Merck & Co. / FDA · fda.gov · States explicitly that the vaccine has not been shown to protect against strains a person has already been exposed to; notes reduced efficacy in women with existing infection
Tomljenovic L, Shaw CA — Human papillomavirus (HPV) vaccine policy and evidence-based medicine
Annals of Medicine, 2013 · University of British Columbia · Analysis of trial methodology, adjuvant selection, and adverse event reporting in HPV vaccine pre-licensure data
Slade BA et al. — Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
JAMA, 2009 · First large post-licensure VAERS analysis for Gardasil · Reports spectrum of adverse events including syncope, POTS, Guillain-Barré, death
Lazarus R et al. — Electronic Support for Public Health–Vaccine Adverse Event Reporting System (ESP:VAERS)
Harvard Pilgrim Health Care / HHS, 2011 · Grant R18 HS017045 · Concluded that fewer than 1% of vaccine adverse events are reported to VAERS · Basis for underreporting estimates used in VAERS data interpretation
Harper DM, DeMars LR — HPV vaccines — A review of the first decade
Gynecologic Oncology, 2017 · Dr. Diane Harper, principal Gardasil trial researcher · Reassessment of population-level benefit in countries with robust pap screening programs; questions of risk-benefit at individual level
Go Deeper
Related: Breast Health & Mammography
Radiation, compression, false-positive cascade, informed consent in breast screening
Go deeper →Related: Feminine Care
What is in conventional feminine hygiene products — dioxins, fragrance, chlorine bleaching
Go deeper →Related: HRT & Bioidentical Hormones
Oral contraceptives as cervical cancer cofactors — understanding the hormonal picture
Go deeper →